A multicenter phase II study of single-agent enzastaurin in previously treated multiple myeloma. 2014

Eric Jourdan, and Veronique Leblond, and Hervé Maisonneuve, and Karim A Benhadji, and Anwar M Hossain, and Tuan S Nguyen, and James E Wooldridge, and Philippe Moreau
Centre Hospitalier Regional Universitaire de Nîmes , Nîmes , France.

Enzastaurin is an oral serine/threonine kinase inhibitor of the protein kinase C (PKC) and phosphatidylinositol 3 (PI3) kinase/Akt pathways that induces apoptosis in multiple myeloma (MM) cell lines in a caspase-independent manner. A phase II study was conducted to assess response rate, time to progression (TTP), safety and biomarker association with clinical outcomes after monotherapy with the PKC inhibitor enzastaurin in previously treated patients with MM. Eligible patients (n = 14) were treated with enzastaurin 250 mg twice daily after receiving loading doses on day 1. One minimal response was observed. The median TTP was 5.11 months. There were two grade 3 adverse events, anemia and prolonged QTc interval, and no grade 4 adverse events. Single-agent enzastaurin was well tolerated but not effective in this heavily pretreated population with MM.

UI MeSH Term Description Entries
D007211 Indoles Benzopyrroles with the nitrogen at the number one carbon adjacent to the benzyl portion, in contrast to ISOINDOLES which have the nitrogen away from the six-membered ring.
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009101 Multiple Myeloma A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY. Myeloma, Plasma-Cell,Kahler Disease,Myeloma, Multiple,Myeloma-Multiple,Myelomatosis,Plasma Cell Myeloma,Cell Myeloma, Plasma,Cell Myelomas, Plasma,Disease, Kahler,Multiple Myelomas,Myeloma Multiple,Myeloma, Plasma Cell,Myeloma-Multiples,Myelomas, Multiple,Myelomas, Plasma Cell,Myelomas, Plasma-Cell,Myelomatoses,Plasma Cell Myelomas,Plasma-Cell Myeloma,Plasma-Cell Myelomas
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000369 Aged, 80 and over Persons 80 years of age and older. Oldest Old
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D016896 Treatment Outcome Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series. Rehabilitation Outcome,Treatment Effectiveness,Clinical Effectiveness,Clinical Efficacy,Patient-Relevant Outcome,Treatment Efficacy,Effectiveness, Clinical,Effectiveness, Treatment,Efficacy, Clinical,Efficacy, Treatment,Outcome, Patient-Relevant,Outcome, Rehabilitation,Outcome, Treatment,Outcomes, Patient-Relevant,Patient Relevant Outcome,Patient-Relevant Outcomes

Related Publications

Eric Jourdan, and Veronique Leblond, and Hervé Maisonneuve, and Karim A Benhadji, and Anwar M Hossain, and Tuan S Nguyen, and James E Wooldridge, and Philippe Moreau
August 1977, Cancer treatment reports,
Eric Jourdan, and Veronique Leblond, and Hervé Maisonneuve, and Karim A Benhadji, and Anwar M Hossain, and Tuan S Nguyen, and James E Wooldridge, and Philippe Moreau
June 1994, American journal of clinical oncology,
Eric Jourdan, and Veronique Leblond, and Hervé Maisonneuve, and Karim A Benhadji, and Anwar M Hossain, and Tuan S Nguyen, and James E Wooldridge, and Philippe Moreau
April 2022, BMC medicine,
Eric Jourdan, and Veronique Leblond, and Hervé Maisonneuve, and Karim A Benhadji, and Anwar M Hossain, and Tuan S Nguyen, and James E Wooldridge, and Philippe Moreau
October 2012, Lung cancer (Amsterdam, Netherlands),
Eric Jourdan, and Veronique Leblond, and Hervé Maisonneuve, and Karim A Benhadji, and Anwar M Hossain, and Tuan S Nguyen, and James E Wooldridge, and Philippe Moreau
November 2019, Lung cancer (Amsterdam, Netherlands),
Eric Jourdan, and Veronique Leblond, and Hervé Maisonneuve, and Karim A Benhadji, and Anwar M Hossain, and Tuan S Nguyen, and James E Wooldridge, and Philippe Moreau
August 2000, American journal of clinical oncology,
Eric Jourdan, and Veronique Leblond, and Hervé Maisonneuve, and Karim A Benhadji, and Anwar M Hossain, and Tuan S Nguyen, and James E Wooldridge, and Philippe Moreau
January 2018, In vivo (Athens, Greece),
Eric Jourdan, and Veronique Leblond, and Hervé Maisonneuve, and Karim A Benhadji, and Anwar M Hossain, and Tuan S Nguyen, and James E Wooldridge, and Philippe Moreau
April 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
Eric Jourdan, and Veronique Leblond, and Hervé Maisonneuve, and Karim A Benhadji, and Anwar M Hossain, and Tuan S Nguyen, and James E Wooldridge, and Philippe Moreau
December 2007, British journal of cancer,
Eric Jourdan, and Veronique Leblond, and Hervé Maisonneuve, and Karim A Benhadji, and Anwar M Hossain, and Tuan S Nguyen, and James E Wooldridge, and Philippe Moreau
November 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
Copied contents to your clipboard!